The dark zone of CNS relapse in DLBCL
In this issue of Blood, Alduaij and colleagues report on central nervous system (CNS) relapse rates in a retrospective cohort of patients with high-grade B
Related Articles
1-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial – PubMed
In our study, treatment with risk-adapted, MR-guided SABR resulted in a high one-year local control and survival rate and could keep half of the patients…
MESA DEBATE “CLAVES en Linfoma del Manto” #CLAVESenLCM
Moderadores:Dr. Raúl Córdoba Mascuñano. Hospital Universitario Fundación Jiménez Díaz, MadridDra. Ana Marín-Niebla. Hospital Universitario Vall d´Hebron, Bar…
The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial…
Global Collaborations Help Expand Surgical Workforce Opportunities for Women
Learn how COSECSA is growing the women surgeon workforce in Sub-Saharan Africa while ensuring quality training standards.
I chaired the NHS and hardly believed it: sewage flows into sinks
The outgoing chairman of NHS England is full of praise for its staff but says the service is ‘sclerotic’ and relies too heavily on politicians
Chilblains in immune-mediated inflammatory diseases: a review
Abstract. Chilblains were first described over a hundred years ago as cutaneous inflammatory lesions, typically on the digits, occurring on cold exposure.
Mike Johnson says Democrats ‘are flailing right now’
He says the flurry of Republican activity has left them rudderless.
Management of Locally Advanced Rectal Cancer: ASCO Guideline
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
Management of high-grade neuroendocrine neoplasms: impact of functional imaging
Gastroenteropancreatic neuroendocrine neoplasms(GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO introduced the neuroendocrine tumour(NET) grade 3 (G3) subgroup,…
FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
